In the present study, we tested this hypothesis and found that co-treatment with ROS1 inhibitors and FAK inhibitors conferred synergistic anti-tumor effects in CDH1-deficient mice model of DGC in vitro and in vivo. This evidence concerns the gene ROS1 and neoplasm.